Rimini Street (NASDAQ:RMNI – Get Free Report) and Portage Biotech (NASDAQ:ALP – Get Free Report) are both small-cap technology companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.
Valuation and Earnings
This table compares Rimini Street and Portage Biotech”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rimini Street | $421.54 million | 0.90 | $37.10 million | $0.08 | 50.94 |
| Portage Biotech | $97,000.00 | 63.76 | -$38.63 million | ($409.00) | -0.01 |
Profitability
This table compares Rimini Street and Portage Biotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rimini Street | 1.69% | -53.91% | 3.24% |
| Portage Biotech | N/A | N/A | N/A |
Analyst Ratings
This is a summary of current ratings and recommmendations for Rimini Street and Portage Biotech, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rimini Street | 0 | 3 | 3 | 0 | 2.50 |
| Portage Biotech | 1 | 2 | 0 | 0 | 1.67 |
Rimini Street presently has a consensus price target of $6.33, indicating a potential upside of 55.42%. Portage Biotech has a consensus price target of $12.50, indicating a potential upside of 213.28%. Given Portage Biotech’s higher possible upside, analysts plainly believe Portage Biotech is more favorable than Rimini Street.
Insider & Institutional Ownership
73.8% of Rimini Street shares are held by institutional investors. Comparatively, 13.4% of Portage Biotech shares are held by institutional investors. 42.0% of Rimini Street shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Risk and Volatility
Rimini Street has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Portage Biotech has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.
Summary
Rimini Street beats Portage Biotech on 11 of the 14 factors compared between the two stocks.
About Rimini Street
Rimini Street, Inc. provides enterprise software products, services, and support. The company engages in the provision of support services for Oracle and SAP enterprise software products. It also provides Rimini ONE, an outsourcing option that offers a set of unified and integrated services to run, manage, support, customize, configure, connect, protect, monitor, and optimize its clients’ application, database, and technology enterprise software; Rimini Support, a mission-critical support for Oracle, SAP, proprietary and open-source database, and technology software; Rimini Manage, a suite of managed services for application and database software; Rimini Protect, a suite of personalized software security services and solutions; and Rimini Connect, a suite of managed interoperability solutions for browsers, operating systems, and email systems. In addition, the company offers Rimini Watch, a suite of observability solutions that include monitoring and system health check solutions; Rimini Consult, a suite of professional services for clients’ enterprise software customization, configuration, implementation, integration, interoperability, migration, staff augmentation, and other project needs; and Rimini Custom, a program that expands support and related services to a broader portfolio of enterprise software. The company serves Fortune 500 companies and Fortune Global 100 companies across various industries. It sells its solutions primarily through direct sales organizations in North America, Latin America, Europe, Africa, the Middle East, Asia, and the Asia-Pacific. The company was incorporated in 2005 and is headquartered in Las Vegas, Nevada.
About Portage Biotech
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company’s product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Receive News & Ratings for Rimini Street Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rimini Street and related companies with MarketBeat.com's FREE daily email newsletter.
